If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Trading Update

7 Nov 2016 07:00

RNS Number : 4343O
Ideagen PLC
07 November 2016
 

7 November 2016

Ideagen plc

("Ideagen" or the "Company")

 

Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, today provides an update on trading for the six months ended 31 October 2016.

 

The Board is pleased to report that trading has remained strong in the first half of the financial year.

 

Revenue and adjusted EBITDA are expected to show a significant increase over the same period last year through a combination of organic growth and the acquisition of Covalent. The Group expects to report organic revenue growth of approximately 16% together with a small contribution from Covalent which was acquired in August 2016. The integration of Covalent is now complete and the Company expects an increased level of contribution in the second half. Consequently, the Company continues to trade in line with market expectations for the full year to 30 April 2017.

 

Cash generation in the period was strong and the Company maintains a robust balance sheet with no debt. The cash balance at the period end was £4.8 million (30 April 2016: £6.3 million), after the payment of £3.8 million for acquisitions and associated costs.

 

David Hornsby, Chief Executive Officer of Ideagen, commented: "This has been a good start to the financial year. Strong trading has been driven by demand across all key vertical markets and continued momentum with our cloud-based Enlighten solution. The market opportunity remains large and long term, and consequently, the Board is optimistic about the Group's continued growth prospects."

 

 

Enquiries:

Ideagen plc

Tel: 01629 699100

David Hornsby, Chief Executive

Graeme Spenceley, Finance Director

finnCap (Nominated Adviser and Broker)

Tel: 020 7220 0500

Stuart Andrews / James Thompson (Corporate Finance)

Stephen Norcross (Corporate Broking)

Alma PR

Tel: 020 8004 4218

Hilary Buchanan

Josh Royston

About Ideagen plc

Ideagen is a UK company quoted on the London Stock Exchange AIM market (Ticker: IDEA.LN). Ideagen is a supplier of Information Management software with operations in the UK, the United States and the Middle East. The Company specialises in eGRC (Enterprise Governance, Risk and Compliance) and Healthcare solutions for organisations operating within highly regulated industries. With an excellent portfolio of software products, Ideagen is able to provide complete content lifecycle solutions that enable organisations to meet their Regulatory and Quality Compliance standards, helping them to reduce costs and improve efficiency.

The Group has a customer base of over 2,200 organisations using the Ideagen suite of products, including many blue chip names such as BAE Systems, Emirates, Shell and the European Central Bank as well as 150 hospitals in the UK and US.

For further information please visit www.ideagen.com

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTVZLFBQFFFFBQ
Date   Source Headline
20th Apr 20221:01 pmGNWForm 8.3 - [Ideagen plc - 19 04 2022] - (HHL)
20th Apr 202212:58 pmGNWForm 8.3 - [Ideagen plc - 19 04 2022] - (CGWL)
20th Apr 202212:54 pmRNSForm 8.3 - Ideagen plc
20th Apr 202212:34 pmRNSForm 8.3 - Ideagen Plc
20th Apr 202212:28 pmRNSForm 8.3 - Ideagen PLC
20th Apr 202211:56 amBUSForm 8.3 - Ideagen Plc
20th Apr 202211:38 amRNSForm 8.5 (EPT/RI)
20th Apr 202211:11 amRNSForm 8 (DD) - Ideagen Plc
20th Apr 202210:52 amGNWForm 8.3 - Ideagen
20th Apr 202210:42 amGNWForm 8.3 - Ideagen Plc
20th Apr 20229:34 amRNSForm 8.5 (EPT/RI) - Ideagen Plc
20th Apr 20229:11 amRNSForm 8.5 (EPT/RI)
19th Apr 20225:44 pmBUSForm 8.3 - Ideagen PLC
19th Apr 20225:28 pmRNSForm 8.3 - Ideagen PLC
19th Apr 20225:19 pmRNSForm 8.3 - Ideagen plc
19th Apr 20221:32 pmRNSForm 8.3 - Ideagen PLC
19th Apr 20227:00 amRNSResponse to Cinven Statement
14th Apr 20225:26 pmRNSPossible Offer for Ideagen PLC
13th Apr 202212:00 pmRNSIssue of shares, Director/PDMR Shareholding & TVR
8th Apr 202212:30 pmRNSExercise of Options and Total Voting Rights
1st Apr 20227:00 amRNSTotal Voting Rights
25th Mar 20226:00 pmRNSDirector/PDMR Shareholding
14th Mar 20227:00 amRNSIssue of Equity and TVR
1st Mar 20222:35 pmRNSDirector/PDMR Shareholding
1st Mar 20222:30 pmRNSTotal Voting Rights
11th Feb 20225:45 pmRNSIssue of Shares under SIP and TVR
11th Feb 202211:01 amRNSHolding(s) in Company
9th Feb 20227:01 amRNSAcquisition of MailManager
9th Feb 20227:00 amRNSChange of Adviser
1st Feb 20228:30 amRNSTotal Voting Rights
13th Jan 20227:01 amRNSGrant of awards under the Ideagen LTIP
13th Jan 20227:00 amRNSUnaudited Interim Results
12th Jan 202212:02 pmRNSIssue of Shares Under SIP and Total Voting Rights
4th Jan 20222:45 pmRNSTotal Voting Rights
14th Dec 20214:30 pmRNSIssue of Shares Under SIP and Total Voting Rights
13th Dec 20216:00 pmRNSHolding(s) in Company
9th Dec 20219:05 amRNSSecond Price Monitoring Extn
9th Dec 20219:00 amRNSPrice Monitoring Extension
9th Dec 20217:00 amRNSResult of Placing and PrimaryBid Offer
8th Dec 20214:50 pmRNSRetail Offer by PrimaryBid
8th Dec 20214:49 pmRNSProposed Placing of Ordinary Shares
1st Dec 20214:15 pmRNSTotal Voting Rights
30th Nov 20217:00 amRNSCapital Markets Day
15th Nov 20217:00 amRNSHalf Year Trading Update and Acquisition
12th Nov 20214:46 pmRNSIssue of new shares under the SIP and TVR
9th Nov 20217:00 amRNSAcquisition of CompliSpace
1st Nov 202111:52 amRNSTotal Voting Rights
28th Oct 20215:30 pmRNSResult of AGM
27th Oct 20217:00 amRNSAcquisitions of Audit Analytics and Ai XPRT
22nd Oct 20217:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.